Bio & Pharma
S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
Optieum will provide an antibody for targeted diseases for the treatment CAR-NK
By Dec 14, 2022 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer](https://www.kedglobal.com/data/ked/image/2022/12/14/ked202212140013.437x.0.jpg)
South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on joint research in blood cancer.
Optieum is developing a platform to find a single-chain fragment variable (ScFv) structure that boosts the effects of treatment of targeted diseases.
Under the agreement, GI Cell will perform a feasibility study on development of new treatments by applying Optieum's antibody targeting blood cancer to the next-generation anti-cancer treatment CAR-NK cell therapy.
Such therapy combines a chimeric antigen receptor (CAR) that specifically reacts to cancer and natural killer (NK) cells.
If GI Cell pursues the commercial application of the developed treatment, it will pay the technical royalty or milestone and other payments to Optieum for each stage of development and commercialization.
GI Cell CEO Hong Chun-pyo said, "We expect that this antibody has the potential to accelerate the development of our new CAR-NK medication."
Write to Ji-Hyun Lee at bluesky@hankyung.com
More to Read
-
-
-
Corporate strategyHyundai Glovis to spend $6.5 billion, seek M&As for expansion
Jun 28, 2024 (Gmt+09:00)
-
Korean chipmakersSouth Korea sets sights on fostering EDA tech to win HBM chip war
Jun 28, 2024 (Gmt+09:00)
-
Comment 0
LOG IN